EQRx to Present at the 40th Annual J.P. Morgan Healthcare Conference
EQRx, a new pharmaceutical company focused on providing innovative medicines at lower costs, has announced that CEO Melanie Nallicheri will present at the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
EQRx, a new pharmaceutical company focused on providing innovative medicines at lower costs, has announced that CEO Melanie Nallicheri will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10 at 3:45 p.m. ET. The presentation will be available live and archived on the company's investor website. EQRx aims to disrupt the pharmaceutical industry with a growing catalog of medicines and strategic partnerships, emphasizing efficient development and delivery.
Details
News Market Reaction – EQRX
The recorded move for EQRX in the trading session of this news was +3.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced that Melanie Nallicheri, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10 at 3:45 p.m. ET.
A live and archived webcast of the presentation will be available by visiting the Investors section of the Company’s website at investors.eqrx.com.
About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRxInc, LinkedIn, Instagram: @eqrxinc.
EQRx™ and Remaking Medicine™ are trademarks of EQRx, Inc.
EQRx Contacts:
Media:
Dan Budwick
1AB
dan@1abmedia.com
Investors:
investors@eqrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.